NME/NM23 family member 5Genealiases: CILD48 · NDK5 · NM23-H5 · NM23H5 · RSPH23
Q-omics provides the consensus-scored NME5 profile across patient tissues and cancer cell-line models. NME5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, NME5 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, NME5 RNA expression shows 17,916 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KICH, and UVM as cancer lineages where NME5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NME5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NME5 survival associations across molecular data types. NME5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NME5 RNA expression–survival associations across cancer types. High NME5 expression shows favorable associations in BRCA, ACC, UCEC, KIRP, LAML and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for NME5 RNA expression.
This table summarizes NME5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NME5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NME5 shows lower tumor expression in KICH, THCA, LUSC, LUAD, BLCA and KIRC. The KICH box plot shows higher NME5 RNA expression in normal versus tumor tissue (log2 FC = −3.502, t-test p < 0.001).
This table shows molecular features associated with NME5 in patient tissues and cancer cell lines. In patient samples, NME5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NME5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
